President Trump just nominated Dr. Heidi Overton to run the FDA, and the pharmaceutical-industrial complex is already sounding alarms — because a surgeon who questions combined vaccine schedules and opposes gender mutilation for minors might actually hold drugmakers accountable.

The FDA employs roughly 18,000 people and regulates every drug, device, and food product Americans consume. For decades it has functioned less as a watchdog than a lapdog for the industry it oversees. Overton's record suggests she might break that pattern — and that is precisely why Washington's permanent class is nervous.

Overton is currently the White House deputy assistant to the president for domestic policy. Before that, she worked at the America First Policy Institute, where she wrote papers opposing so-called gender-affirming care for minors and questioned the FDA's decision to allow medication abortion via telehealth. She backed Trump's August 10 executive order revisiting the childhood vaccine schedule, calling it "a historic action." She also supported producing individual vaccines for measles, mumps, and rubella instead of the combined MMR shot, saying, "We want parents to be informed about the timing and to have the option to separate them out."

NPR framed the executive order as "dredging up debunked theories linking vaccines to autism" and quoted Obama-era FDA principal deputy commissioner Joshua Sharfstein saying there's "no science" to support separating the MMR vaccine. But Sharfstein also let something telling slip: successful FDA commissioners, he said, need "a strong spine" because "there are political pressures, there are business pressures, there are advocacy pressures coming all the time." Read that carefully — a former top FDA official is admitting the agency faces constant pressure from the pharmaceutical industry and presenting that as just the way things work. Overton's sin, in establishment eyes, is that she might actually resist those pressures.

The confirmation fight is already a test of Republican resolve. Senator Patty Murray, Democrat of Washington, says she'll vote no. Senator Bill Cassidy, a Louisiana Republican and gastroenterologist, has "voiced concerns" on social media but won't say how he'll vote, according to NPR. Meanwhile, North Dakota Republican Kevin Cramer has placed a blanket hold on all Trump nominees over a separate property rights dispute, the Daily Caller reported. Cramer is furious that the Fish and Wildlife Service kept a Biden-era wetlands conservation rule preventing farmers from installing drainage tiles near federal easements. "There won't be another nominee confirmed until something changes," Cramer said.

So the landscape is this: an FDA nominee who threatens the drug industry's cozy arrangement with regulators, a Democrat lining up against her, a Republican doctor hedging, and another Republican holding the entire confirmation process hostage over a land-use fight with the bureaucracy. The same Senate that rubber-stamped every pharmaceutical-friendly commissioner for decades is suddenly concerned about "expertise" when someone walks in who might ask hard questions.

Overton has already shown more willingness to challenge the consensus than any FDA leader in recent memory. Whether she gets confirmed depends on whether Senate Republicans care more about reforming a broken agency or preserving the comfortable arrangements that got us here.